In the phase 3 LIBERTY study, the investigational monoclonal antibody, VYD2311, had significantly fewer adverse events than an mRNA COVID-19 vaccine, and it did not blunt vaccine-induced neutralizing titers when the two were given together.
|Articles|February 19, 2021
First Dose of Pfizer-BioNTech COVID-19 Vaccine Reduces Symptomatic Disease Significantly
Author(s)John Parkinson
An Israeli study finds it had an 85% effect in lowering disease 2 to 4 weeks after administration of the initial vaccination.
Advertisement
The first dose of the Pfizer-BioNTech COVID-19 vaccine is showing it reduces symptomatic disease by 85%, 2 to 4 weeks after vaccination.
The findings were published in
“Our data show substantial early reductions in SARS-CoV-2 infection and symptomatic COVID-19 rates following first vaccine dose administration,” the investigators wrote.
The study was conducted in Israel at the Sheba Medical Center, which is the country’s largest hospital. The medical center has 9647 health care workers (HCWs), and the entire staff was eligible for vaccination, excluding those who had COVID-19 previously.
They began mass vaccination on December 19, 2020.
“Compared with a symptomatic COVID-19 rate of 5·0 per 10 000 person-days in unvaccinated HCWs, disease rates were 2·8 and 1·2 per 10 000 person-days on days 1–14 and days 15–28 after the first dose of the vaccine, respectively,” the investigators wrote about the results. “Adjusted rate reductions of COVID-19 disease were 47% (95% CI 17–66) and 85% (71–92) for days 1–14 and days 15–28 after the first dose, respectively.”
The data suggested that during this period of limited vaccine supply, the investigators said it lent support for getting the first vaccine to more people, even if there are delays in getting the second dose.
“Early reductions of COVID-19 rates provide support of delaying the second dose in countries facing vaccine shortages and scarce resources, so as to allow higher population coverage with a single dose,” the investigators concluded.
Advertisement
Related to this article
After 2 adults died of West Nile virus in central North Carolina this month, this FAQ explains how the mosquito-borne virus spreads, who faces the greatest risk of severe neuroinvasive disease, and how clinicians can diagnose, manage, and help prevent infection when no vaccine or antiviral treatment exists.
North Carolina health officials confirmed two West Nile virus deaths among adults in the central part of the state, where CDC data show 11 human cases this season.
A 39-year-old unvaccinated Franklin County woman has died after a recent measles diagnosis. Nationally, numbers continue to increase and the US has passed 4,000 cases.
The National Foundation for Infectious Diseases (NFID) recently held its respiratory season kick-off, which included the release of its annual respiratory disease survey. This year, the survey revealed the gap between vaccine support and uptake. Robert Hopkins Jr, MD, medical director of NFID delves deeper into the findings of the survey and the vaccine uptake challenges associated with certain immunizations.
Detection of the virulent neurotropic fungus Cladophialophora bantiana in clinical samples, primarily CNS tissue, increased four-fold in the period from 2023 to 2025.
CDC reports 8,750 confirmed Bundibugyo virus cases and 4,208 deaths, making the DRC outbreak the second-largest Ebola outbreak on record.
Pritelivir (Hovilpri) healed all lesions by day 28 in 63% of immunocompromised adults with refractory HSV versus 34% with investigator's choice in the phase 3 PRIOH-1 trial.
Advertisement
Advertisement